Aspirin is a familiar drug, born on March 6, 1899, first used for antipyretic and analgesic, and now mostly used to prevent thrombotic disorders. But you may not know that the drug has other uses. A recent study suggests that taking aspirin can improve survival rates for colorectal cancer patients. A Norwegian census study reported in the JournalofClinicalOncology in 2015 showed that the use of aspirin after colorectal cancer diagnosis improved colorectal cancer-specific survival rates. The study retrospectively analyzed patients diagnosed with colorectal cancer in the Norwegian Cancer Registry from 2004 to 2011 who had a prescription for aspirin in the Norwegian Prescription Database. The registry covers more than 99% of the Norwegian population. The inclusion criterion was aspirin use for more than 6 months after colorectal diagnosis. A total of 23,162 patients diagnosed with colorectal cancer were included in the analysis, and 6,102 (26.3%) were taking aspirin after definitive diagnosis. The median follow-up period was 3 years. Multivariate analysis showed that patients taking aspirin after diagnosis of colorectal cancer had significantly better specific survival and overall survival. Therefore, aspirin can be an effective drug for secondary prevention (early detection, diagnosis, and treatment) of colorectal cancer.